Hematopoietic prostaglandin D synthase (HPGDS) is an attractive target for the treatment of a variety of diseases, including allergic diseases and Duchenne muscular dystrophy.442 To date, several types of H-PGDS inhibitors have been developed as therapies for allergic and inflammatory responses. The gene discussed is HPGDS; the disease is Duchenne muscular dystrophy.